BIIB Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of 10.87% compared to Biogen's net margin of 32.59%. Biogen's return on equity of 10.33% beat Eli Lilly and's return on equity of 80.24%.

Biogen has a consensus price target of $200.12, signalling upside risk potential of 52.39%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 23.5%. Given that Biogen has higher upside potential than Eli Lilly and, analysts believe Biogen is more attractive than Eli Lilly and.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Biogen pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Biogen quarterly revenues are $2.5B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Biogen's net income of $266.7M is lower than Eli Lilly and's net income of $4.4B. Notably, Biogen's price-to-earnings ratio is 11.74x while Eli Lilly and's PE ratio is 69.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.98x versus 16.42x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 10.87% compared to Biogen's net margin of -117.16%. Biogen's return on equity of 10.33% beat Moderna's return on equity of -29.09%.

Biogen has a consensus price target of $200.12, signalling upside risk potential of 52.39%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 92.79%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are larger than Moderna quarterly revenues of $956M. Biogen's net income of $266.7M is higher than Moderna's net income of -$1.1B. Notably, Biogen's price-to-earnings ratio is 11.74x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.98x versus 3.36x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of 10.87% compared to Biogen's net margin of -747.33%. Biogen's return on equity of 10.33% beat Sage Therapeutics's return on equity of -63.59%.

Biogen has a consensus price target of $200.12, signalling upside risk potential of 52.39%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could grow by 3.55%. Given that Biogen has higher upside potential than Sage Therapeutics, analysts believe Biogen is more attractive than Sage Therapeutics.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.304%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are larger than Sage Therapeutics quarterly revenues of $12.8M. Biogen's net income of $266.7M is higher than Sage Therapeutics's net income of -$95.8M. Notably, Biogen's price-to-earnings ratio is 11.74x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.98x versus 11.45x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 10.87% compared to Biogen's net margin of 31.35%. Biogen's return on equity of 10.33% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Biogen has a consensus price target of $200.12, signalling upside risk potential of 52.39%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $497.84 which suggests that it could grow by 2.97%. Given that Biogen has higher upside potential than Vertex Pharmaceuticals, analysts believe Biogen is more attractive than Vertex Pharmaceuticals.

Biogen has a beta of 0.057, which suggesting that the stock is 94.303% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.617%.

Biogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biogen pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Biogen quarterly revenues are $2.5B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Biogen's net income of $266.7M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Biogen's price-to-earnings ratio is 11.74x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biogen is 1.98x versus 11.38x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.